A Multicentre, Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled Study With Open Label Extension to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Active Ulcerative Colitis
Latest Information Update: 28 Jun 2023
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 19 Jul 2019 Status changed from active, no longer recruiting to completed.
- 12 Jul 2019 This trial has been completed in Sweden.
- 12 Apr 2019 Planned End Date changed from 7 May 2019 to 19 Jun 2019.